Our Leadership Team
Douglas (Doug) Reynolds
Co-founder and President
Doug has a BSc, MBA, and over 30 years of Canadian pharmaceutical experience with extensive sales and marketing experience at several large multinational companies such as Lederle Laboratories, Syntex Inc., Hoffmann-La Roche (Director of Sales, Director of Marketing), Sanofi Inc. (VP, Sales and Marketing). In 2001, he founded, and led as President, Oryx Pharmaceuticals Inc., a Canadian-based specialty pharmaceutical company. Under Doug’s leadership Oryx grew rapidly and was acquired by Sepracor Inc. in 2008 to expand its North American footprint. Doug remained as President from 2008 to 2019 and the company tripled its Canadian sales during his tenure. Throughout his career, Doug has executively led strong entrepreneurial teams to achieve numerous commercially successful launches (e.g., SUPRAX, TICLID, AVAPRO, PLAVIX, TRILEPTAL, NIASPAN, ANGIOMAX, CUBICIN, APTIOM, LATUDA). Doug co-founded KYE Pharmaceuticals in 2019.
Co-founder and VP, Scientific Affairs and Compliance
Eryn has a BSc (Applied Biology/Biotechnology), MSc (Human Physiology) and over 25 years of Canadian and global (US/EU) regulatory affairs, medical affairs, and compliance experience. She has extensive experience at several multinational companies (AstraZeneca, Boehringer Ingelheim, Serono) leading to progressive leadership roles growing regulatory, medical, and compliance departmental functions within smaller organizations (Oryx Pharmaceuticals, Sunovion Pharmaceuticals, Verity Pharmaceuticals). She has led numerous regulatory filings and has clinically supported several successful launches (e.g., ANGIOMAX, CUBICIN, APTIOM, LATUDA, IVOZFO) in a wide array of therapeutic areas. Eryn co-Founded KYE Pharmaceuticals in 2019
Under their leadership, Doug and Eryn, have assembled an impressive team of pharmaceutical professionals with decades of combined experience and proven success in executive management, finance, scientific affairs, business development, supply chain management, and commercialization. KYE has been founded on an entrepreneurial spirit that optimizes our team’s strengths and brings unique value to our partners, Canadian health care professionals, and most importantly, our patients. From registration to commercialization, the KYE team creatively addresses the challenges of the Canadian pharmaceutical environment to bring important new medicines to our market as quickly and economically as possible.